XePOHCAS: Prospective, randomized, multicenter, interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature management [TTM]) to standard-of-care post-cardiac arrest intensive care (including TTM) plus xenon by inhalation
Latest Information Update: 05 Apr 2025
At a glance
- Drugs Xenon (Primary)
- Indications Chronic brain damage
- Focus Registrational; Therapeutic Use
- Acronyms XePOHCAS
- Sponsors Invero Pharma
Most Recent Events
- 26 Mar 2025 Planned End Date changed from 15 Dec 2020 to 1 May 2030.
- 26 Mar 2025 Planned primary completion date changed from 15 Jul 2020 to 1 Apr 2029.
- 26 Mar 2025 Planned initiation date changed from 25 May 2018 to 1 Mar 2026.